Conservative management of testicular germ-cell tumors

Nature Clinical Practice Urology

Volumn 4, Issue 10, 2007, Pages 550-560

  Oliver, Tim ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; VINBLASTINE;

ADJUVANT THERAPY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GERM CELL TUMOR; HEARING LOSS; HUMAN; LEUKEMIA; LUNG TOXICITY; LYMPHOCYTOPENIA; METABOLIC SYNDROME X; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; ORGAN PRESERVATION; OSTEOPENIA; OSTEOPOROSIS; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SECOND CANCER; SEMINOMA; SURVIVAL TIME; TESTIS CANCER; TESTIS DISEASE; TESTIS NONSEMINOMA CANCER; TINNITUS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; GERMINOMA; HUMANS; MALE; TESTICULAR NEOPLASMS;

EID: 35048844130     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0905     Document Type: Review

References (86)

1. Oliver RT et al. (1996) Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. Br J Urol 78: 119-124
2. Robinson D et al. (2007) Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96: 529-533
3. Heidenreich et al. (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage 1 nonseminomatous germ cell tumors of the testis: Experience of the German Testicular Cancer Study Group. J Urol 169: 1710-1714
4. Hoff Wanderas E et al. (1990) Serum follicle stimulating hormone - predictor of cancer in the remaining testis in patients with unilateral testicular cancer. Br J Urol 66: 315-317
5. Heidenreich A et al. (2001) The German Testicular Cancer Study G. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 166: 2161-2165
6. Oliver RT et al. (2003) Testis conserving chemotherapy in germ cell cancer: Its potential to increase understanding of the biology and treatment of carcinoma-in-situ. APMIS 111: 86-92
7. Satoh M et al. (2005) Intraoperative, radio-guided sentinel lymph node mapping in laparoscopic lymph node dissection for Stage I testicular carcinoma. Cancer 103: 2067-2072
8. Shamash J et al. (2002) GAMEC - a novel protocol for IGCCCG poor prognosis and relapsing germ cell tumours. In Germ Cell Tumours V, 240-241 (Eds Hamden P et al.) London: Springer
9. Shamash J et al. (2007) A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol 18: 925-930
10. Albers P et al. (1999) Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53: 808-811
11. Oliver RTD et al. (2004) 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hour PET scan response? [abstract]. J Clin Oncol 22 (suppl : 4763
12. Powles T et al. (2007) Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51: 1511-1521
13. Edmonds PM et al. (1993) Risk of a second non-testis malignancy following radiotherapy for stage 1 seminoma. In Abstracts of the BAUS Annual Meeting, 1993 June, Harrogate, 53
14. Zagars GK et al. (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640-647
15. Oliver RTD (1985) Testicular germ call tumours - a model for a new approach to treatment of adult solid tumours. Postgrad Med J 61 123-131
16. Williams SD et al. (1987) Treatment of disseminated germ-cell tumours with Cisplatin, Bleomycin, and either Vinblastine or Etoposide. N Engl J Med 316: 1435-1440
17. Mead GM and Stenning S (1997) International germ cell cancer collaborative group prognostic factor scoring system. J Clin Oncol 5: 594-603
18. Bajorin D et al. (1998) Metastatic germ cell tumours: Modelling for response to chemotherapy. J Clin Oncol 16: 707-715
19. Kaye S et al. (1996) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment of metastatic nonseminamatous germ cell tumour. J Clin Oncol 16: 692-701
20. Hinton S et al. (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97: 1869-1875
21. Boshoff CB et al. (1995) Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 6: 35-40
22. Orchid website [www.orchid-cancer.org.uk]
23. Bhardwa JM et al. (2005) Assessing the size and stage of testicular germ cell tumours: 1984-2003. BJU Int 96: 819-821
24. Agnarsson BA et al. (2006) Testicular germ cell tumours in Iceland: A nationwide clinicopathological study. APMIS 114: 779-783
25. Shamash J et al. (1999) 60% salvage rate for germ cell tumours using sequential m-BOP, surgery and ifosfamide based chemotherapy. Ann Oncol 10: 685-692
26. Pico JL et al. (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16: 1152-1159
27. Motzer RJ et al. (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418
28. Shamash J et al.: GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer 97: 308-314
29. Ravi R et al. (1998) Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 81: 884-888
30. Beck SD et al. (2005) Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 23: 423-430
31. Zuk RJ et al. (1989) Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis. J Clin Pathol 42: 1049-1054
32. Loehrer PJ Sr et al. (1986) Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: A clinicopathological correlation. J Urol 135: 1183-1189
33. Oliver RT (2001) Testicular cancer. Curr Opin Oncol 13: 191-198
34. Shelley M et al. (2003) Testicular germ cell cancer. Evidence-based Oncology 34: 365-373
35. Horwich A et al. (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15: 1844-1852
36. De Wit R et al. (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and at a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629-1640
37. Fosse SD et al. (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/ Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21: 1107-1118
38. Freedman L et al. (11985) Prognostic factors in advanced non-seminomatous germ cell testicular tumours: Results of a multicentre study. Lancet 1: 8-11
39. Freedman LS et al. (1987) Histopathology in the prediction of relapse of patients with stage 1 testicular teratoma treated by orchidectomy alone. On behalf of MRC Testicular Tumour Subgroup (Urological Working Party). Lancet 2: 294-298
40. Leiter E and Brendler H (1967) Loss of ejaculation following bilateral retroperitoneal lymphadenectomy. J Urol 98: 375-378
41. Williams SD et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433
42. Oliver R et al. (2004) Long term follow up of Anglian Germ Cell Cancer Group surveillance versus adjuvant chemotherapy treated stage 1 non-seminoma patients. Urology 63: 556-561
43. Albers P (2007) Management of stage I testis cancer. Eur Urol 51: 34-43
44. Steiner H et al. (2004) Long-term results of laparoscopic retroperitoneal lymph node dissection: A single-center 10-year experience. Urology 63: 550-555
45. Rassweiler J et al. (2006) Laparoscopic and robotic assisted radical prostatectomy - critical analysis of the results. Eur Urol 49: 612-624
46. Stephenson AJ et al. (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer impact of patient selection factors on outcome. J Clin Oncol 23: 2781-2788
47. Donohue JP et al. (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137: 1176-1179
48. Albers P et al. (2006) One course adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminoma [abstract]. J Clin Oncol 24: 4512
49. Tyrrell CJ and Peckham MJ (1976) The response of lymph node metastases of testicular teratoma to radiation therapy. Br J Urol 48: 363-370
50. Williams C (1977) Current dilemmas in the management of non-seminomatous germ cell tumors of the testis. Cancer Treat Rev 4, 275-297.
51. Oliver RTD et al. (1984) Possible new approaches to the management of seminoma of the testis. Br J Urol 56: 729-733
52. Logothetis CJ et al. (1987) Cyclophosphamide and sequential cisplatin for advanced seminoma: Long term follow up 52 patients. J Urol 138: 789-794
53. Bokemeyer C et al. (2004) Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: A pooled analysis of two randomised trials. Br J Cancer 91: 683-687
54. Travis LB et al. (2005) Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97: 1354-1365
55. Warde P et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillanGe: A pooled analysis. J Clin Oncol 20: 4448-4452
56. Oliver RTD (2005) One-dose carboplatin in seminoma. Lancet 366 1526
57. Fossa SD et al. (1999) Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17: 1146
58. Jones WG et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200-1208
59. Logue JP et al. (2003) Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 57 1304-1309
60. Classen J et al. (2004) Para-aortic irradiation for stage I testicular seminoma: Results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90: 2305-2311
61. Oliver RT et al. (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29: 3-8
62. Dieckmann K et al. (2000) Adjuvant treatment of clinical stage 1 seminoma: Is a single course of carboplatin sufficient? Urology 55: 102-106
63. Krage S et al. (2006) Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 17: 276-280
64. Sant M et al. (2007) Ten-year survival and risk of relapse for testicular cancer: A EUROCARE high resolution study. Eur J Cancer 43: 585-592
65. Oliver TD et al. (2005) Pooled analysis of phase II reports of 2 vs 1 course of carboplatin as adjuvant for stage 1 seminoma [abstract]. J Clin Oncol 23: 4572
66. Oliver RTD et al. (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage 1 seminoma: A randomised trial. Lancet 366: 293-300
67. Warde P (2006) Are carboplatin and radiotherapy equally effective for the adjuvant treatment of stage 1 seminoma? Nat Clin Pract Oncol 3: 18-19
68. Loehrer PJ Sr and Bosl GJ (2005) Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol 23: 8566-8569
69. Motzer RJ et al. (2006) Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4: 1038-1058
70. Huddart RA and Joffe JK (2006) Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 18: 693-695
71. Sternswald J et al. (1978) Lymphopenia and change in distribution of human B and T lymphocyte in peripheral blood induced by irradiation for mammary carcinoma. Lancet 1: 1352-1356
72. Fosse S et al. (1989) Long term mobidity after infradiaphragmatic radiotherapy in young men with testicular cancer. Cancer 64: 404-408
73. Nuver J et al. (2005) The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23: 3718-3725
74. Mardiak J et al. (2007) Damage of bone metabolism and osteoporosis in testicular cancer patients [abstract]. J Clin Oncol 25 (suppl): 5052
75. Wilemse P-PM (2007) Bone abnormalities in male germ-cell cancer survivors [abstract]. J Clin Oncol 25(suppl): 5053
76. Oliver R (2006) Epidemiology of testis cancer. In Comprehensive Textbook of Genitourinary Oncology, edn 3, 547-658 (Eds Vogelzang N et al.) Philadephia: Lippincott Williams & Wilkins
77. Oliver RTD (1990) Atrophy, hormones, genes and viruses in aetiology of germ cell tumours. Cancer Surv 9: 263-268
78. Skakkebaek NE et al. (2001) Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. Hum Reprod 16: 972-978
79. Sharpe RM (2003) The 'oestrogen hypothesis' - where do we stand now? Int J Androl 26: 2-15
80. Mahood IK et al. (2006) Cellular origins of testicular dysgenesis in rats exposed in utero to di(n-butyl) phthalate. Int J Androl 29: 148-154
81. Rajpert-De Meyts E (2006) Developmental model for the pathogenesis of testicular carcinoma in situ: Genetic and environmental aspects. Hum Reprod Update 12: 303-323
82. Petersen PM et al. (1999) Semen quality and reproductive hormones before orchlectomy in men with testicular cancer. J Clin Oncol 117: 941-947
83. Hoei-Hansen CE et al. (2007) Towards a non-invasive method for early detection of testicular neoplasia in semen samples by identification of fetal germ cell-specific markers. Hum Reprod 22: 167-173
84. Harisinghani MG et al. (2005) A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: A new method for noninvasive lymph node evaluation. Urology 66: 1066-1071
85. Eggener SE et al. (2007) Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol 177: 937-942
86. Powles T et al. (2003) Novel in-vitro approaches to the treatment of cisplatin resistant germ cell tumours [abstract]. Proc Am Soc Clin Oncol 22: 547